Kiniksa Pharma reports positive Phase 3 rilonacept data in pericarditis

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) rilonacept met its primary and major secondary efficacy endpoints in a Phase 3 recurrent pericarditis trial.

The trial met its primary endpoint of time to pericarditis recurrence at week 24. Treatment with rilonacept, a recombinant fusion protein that blocks inflammatory cytokine signaling, resulted in 96% less risk in recurrent pericarditis events. 

The study also met all key secondary endpoints: 81% of rilonacept recipients maintained clinical response at week 16, compared with 20% of placebo recipients. In addition, 81% of rilonacept recipients had absent or minimal pericarditis symptoms at week 16, compared with 25% of placebo recipients. 

“Combined with a well-tolerated safety profile and a weekly dosing regimen, these data are an important step forward for patients,” CEO and chairman, Sanj Patel, said in a statement.

“We believe rilonacept has the potential to be the first FDA-approved therapy for recurrent pericarditis. We are committed to submitting a supplemental BLA to the FDA later this year and look forward to bringing this potential treatment option to patients as soon as possible,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.